Inspired by Science,
Designed for Patients

Pioneering a new approach to kill cancer directly and through activation of the immune system

Gallop Oncology is a clinical-stage biopharma company leading development of drugs targeting galectin-9, a pivotal oncogenic and immunosuppressive regulator of cancer processes

We are focused on transforming treatment paradigms for both hematologic and solid tumor indications. Our lead asset, LYT-200, has received Fast Track and Orphan Drug Designations for the treatment of acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC). With its dual mechanism of action—direct tumor suppression and immune modulation—LYT-200 represents a novel, differentiated approach in oncology therapeutics.

Gallop Oncology was founded by and is currently a wholly-owned subsidiary of PureTech Health.

Meet Gallop Founders and Leadership

Luba Greenwood, JD

Co-founder & Chief Executive Officer

Read Bio
Aleksandra Filipovic, MD, PhD

Co-founder & Chief Medical Officer

Read Bio

Scientific Advisory Board

Steven Rosen, MD

Executive Vice President and Director emeritus, City of Hope Beckman Research Institute and Cancer Center
Eytan Stein, MD

Chief, Leukemia Service and Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies
Joseph Jurcic, MD

Director, Hematologic Malignancies Section of the Division of Hematology/ Oncology, Colombia University
David Sidransky, MD

Director, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine

Galectin-9:
A Groundbreaking Target

Galectin-9 is a multifaceted protein that is overexpressed in multiple hematologic malignancies and solid tumors. It plays a critical role in tumor progression, immune evasion, and resistance to conventional therapies. Elevated levels of galectin-9 correlate with more aggressive cancers and poor prognosis.

Targeting galectin-9 offers a dual mechanism of action:

Direct Tumor Suppression: Inhibiting galectin-9 induces DNA damage and apoptosis in cancer cells.
Immune Modulation: Galectin-9 disrupts immune surveillance by binding to multiple receptor binding partners including CD45, CD44, 4-1BB, PD-1, DR3, VISTA, CD206, Dectin-1 etc. , facilitating immunosuppression. Inhibition of galectin-9 removes this barrier, restoring immune system efficacy against tumors.

This dual mechanism distinguishes Gallop’s approach from existing therapies, offering a potent strategy to elicit response, maintain quality of life and enhance clinical outcomes.

LYT-200 mechanism

LYT-200: Transforming Oncology Treatment

Gallop’s lead candidate, LYT-200, is a fully human IgG4 monoclonal antibody targeting galectin-9. It is being developed for the treatment of:

Hematological malignancies: including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Solid tumors: including head and neck cancers, with a focus on metastatic disease.

LYT-200 has demonstrated excellent safety and promising initial clinical activity as both a monotherapy and in combination with venetoclax/hypomethylating agents (HMA) in AML/MDS, and with anti-PD-1 therapy in head and neck cancers.

Pipeline Highlights

Received unrestricted Fast Track designation and Orphan Drug designation from the FDA for the treatment of AML

Received Fast Track designation from the FDA for the treatment of head and neck cancers

Our Clinical Trials

Gallop Oncology is advancing LYT-200 through the following clinical trials:

Phase 1/2 Trial in Hematological Malignancies: Evaluating LYT-200 as a monotherapy and in combination with venetoclax/HMA for AML and MDS.
Phase 1/2 Trial in Solid Tumors: Investigating LYT-200 as a monotherapy and in combination with tislelizumab, an anti-PD-1 antibody, in advanced/metastatic head and neck cancers.

Addressing Unmet Clinical Needs

Approximately 150,000 new cases of AML are diagnosed annually worldwide, with more than half of patients failing to respond to initial treatments or relapsing. LYT-200 aims to address the critical unmet need in relapsed/refractory AML, with the potential to broaden its application to the majority of AML patients.
With approximately 900,000 new diagnoses globally each year, head and neck cancers have a dismal prognosis, especially in metastatic cases, where median survival is approximately 10 months. LYT-200 offers a promising new approach for these patients, targeting both the tumor and the immune environment.

Join Us in Transforming Cancer Treatment

Gallop Oncology is inspired by science to design paradigm-shifting medicine for patients' needs that matter most: efficacy, durability and quality of life. We stand for developing innovative, differentiated treatments with the potential to dramatically impact patient outcomes. Our commitment to speed, longevity and care while advancing science and improving lives is unwavering.

For more information on our clinical trials, or to inquire about participation, please contact us at clinicaltrials@puretechhealth.com.